Abstract
For three decades now, researchers have hypothesized that Alzheimer’s Disease (AD) is caused by abnormal production and clearance of amyloid in the brain, leading to a complex series of pathological and toxic events. In recent years, this “amyloid cascade hypothesis” has been expanded upon, with a better understanding of how tau may play a critical role in the mechanisms that lead to neurodegeneration, recognizing it as a potential target for the treatment of Alzheimer’s Disease and a marker for monitoring disease progression. In this interactive symposium, the intricate interaction between amyloid and tau will be examined, and the rationale for emerging therapeutic targets will be discussed. The role of amyloid and tau imaging will be explored.

Learning Objectives:
At the end of this session, participants will be able to:

• Discuss hypothetical models of the relationship between amyloid and tau
• Understand potential roles of amyloid and tau imaging in diagnosis and management
• Recognize how recent knowledge and developments may influence future drug development
Exploring the Interaction between Amyloid and Tau in Alzheimer’s Disease: Implications for Diagnosis, Disease Progression, and Management

Sunday, 29 May 2016: 18.30-20.00
Bella Center, Copenhagen: Hall C

Agenda

18.30-18.45  Introductory Remarks
              John Hardy, UK (Chair)

18.45-19.05  Amyloid and Tau Interactions: How Does Current Knowledge Affect Treatment Targets in AD?
              Bengt Winblad, Sweden

19.05-19.15  Q&A

19.15-19.35  Amyloid and Tau Imaging: What Can They Tell Us, Independently and Together?
              Mark Mintun, USA

19.35-19.55  Panel Discussion
              All

19.55-20.00  Closing Remarks
              John Hardy, UK

Light refreshments provided

John Hardy, PhD  
Professor of Neuroscience, Institute of Neurology, University College London, London, UK

Bengt Winblad, MD, PhD  
Professor, Director, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden

Mark Mintun, MD  
President and Chief Medical Officer, Avid Radiopharmaceuticals, A wholly owned subsidiary of Eli Lilly, Philadelphia PA, USA